F2R and myocardial infarction: Consequently, we here evaluated the potential inhibitory effect of vorapaxar (SCH530348, Zontivity), a PAR-1 antagonist used for secondary prevention of atherothrombotic events in patients with previous myocardial infarct, on STZ-induced diabetic nephropathy.